Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Celyad SA

1C0
Current price
1.21 EUR +0.58 EUR (+91.76%)
Last closed 0.67 EUR
ISIN BE0974260896
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 14 640 932 EUR
Yield for 12 month +75.44 %
1Y
3Y
5Y
10Y
15Y
1C0
21.11.2021 - 28.11.2021

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Address: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

0.46 EUR

P/E ratio

Dividend Yield

Current Year

+102 991 EUR

Last Year

Current Quarter

+14 136 EUR

Last Quarter

+58 564 EUR

Current Year

+33 321 EUR

Last Year

-1 453 995 EUR

Current Quarter

+5 049 EUR

Last Quarter

+33 321 EUR

Key Figures 1C0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -7 513 317 EUR
Operating Margin TTM -22028.57 %
PE Ratio
Return On Assets TTM -38.87 %
PEG Ratio
Return On Equity TTM -361.91 %
Wall Street Target Price 0.46 EUR
Revenue TTM 72 700 EUR
Book Value 0.08 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -68.2 %
Dividend Yield
Gross Profit TTM 5 049 EUR
Earnings per share -1.37 EUR
Diluted Eps TTM -1.37 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 1C0

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 1C0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 1C0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 176.8506
Price Sales TTM 169.7422
Enterprise Value EBITDA -0.32
Price Book MRQ 11.9936

Financials 1C0

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 1C0

For 52 weeks

0.21 EUR 0.63 EUR
50 Day MA 0.26 EUR
Shares Short Prior Month
200 Day MA 0.31 EUR
Short Ratio
Shares Short
Short Percent